ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
6 July 2021 - - US-based ANI Pharmaceuticals, Inc (NASDAQ: ANIP) has re-filed its supplemental new drug application for Cortrophin Gel with the US Food and Drug Administration, the company said.

ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.

The company focuses on niche and high barrier to entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations.